AliveCor Kardiaband EKG reader gets FDA approval as the first medical device accessory for the Apple Watch
The Food and Drug Administration has just cleared AliveCor's Kardiaband EKG reader as the first medical device accessory for the Apple Watch. — Europe has been able to use …
Context & Ripple Effects
AliveCor first showed off this wristband back in March 2016, when Vic Gundotra's team was still waiting on the FDA for a heart monitor built around the Apple Watch. The clearance now makes it the first medical device accessory cleared for the watch, and it lands just weeks before Bloomberg reported that Apple itself is developing an EKG monitor for the device — putting AliveCor's accessory on a collision course with its host platform.
The approval matters because it establishes that a third-party strap can carry regulated diagnostic capability on Apple's hardware, not just fitness tracking.
First-order effects
- AliveCor gains a regulated, shipable product for US Apple Watch owners while rivals have nothing cleared, giving it a temporary monopoly on wrist-based EKG readings.
Second-order effects
- Apple's in-house response arrives a year later when the Series 4 ECG feature goes live with watchOS 5.1.2, commoditizing the single-lead accessory and pushing AliveCor upmarket — which is exactly where it lands with the six-lead KardiaMobile 6L cleared at $150 in 2019.
Third-order effects
- If the pattern holds, consumer wearables become a standing FDA clearance category rather than one-off approvals — a path that culminates in the 2024 qualification of Apple's AFib history feature under the FDA's MDDT program for use in clinical studies.
The trend: Wrist-worn devices are moving from fitness accessories to FDA-cleared medical diagnostics, with platform owners like Apple absorbing single-function accessories and third parties retreating to higher-acuity products.